Lates News

According to a research report released by Open Source Securities on March 24th, Dana Bio (920009.SH) was given a "buy" rating. The main reasons for the rating include: 1) The company's early diagnosis specialty in invasive fungal diseases has a market share of over 30%; 2) The expanding demand for in vitro diagnostics, with the Chinese pathogenic microorganism diagnostic market expected to exceed one billion yuan by 2030; 3) The mortality rate of invasive fungal diseases is 27.6% and early diagnosis is crucial; 4) Dana Bio has two exclusive domestic products, a total of 91 domestic patents, and is involved in 10 major technology projects. (Daily Economic News)